XELOX与FOLFOX6治疗结直肠癌的临床疗效比较

Comparison of Clinical Efficacy of XELOX and FOLFOX6 for Rectal Cancer

目的观察XELOX与FOLFOX6治疗结直肠癌的临床效果。方法选择来我院治疗的57例结直肠癌患者,随机分为观察组(27例)与对照组(30例)。对照组患者接受奥沙利铂+氟脲嘧啶+亚叶酸钙治疗,观察组患者接受奥沙利铂+卡培他滨治疗,2组患者均接受2个周期以上的化疗。2组患者均采取调强适形放疗,60 Gy-70 Gy/33 f-39 f为放疗剂量。依照WHO标准对2组的客观疗效进行评价,并用RTOG与WHO标准对放化疗所产生的急性不良反应予以评价。结果治疗有效率观察组为81.5%,对照组为73.3%;患者中位疾病无进展的生存时间观察组是16个月,对照组18个月,1年的生存率观察组为87.6%,对照组为83.4%;以上数据2组比较不具有统计学意义(P>0.05)。在不良反应方面,手足综合征在观察组中较为显著(P<0.05);其他不良反应的发生率对照组较高,但差异不具有统计学意义(P>0.05)。结论 XELOX与FOLFOX6在结直肠癌的治疗中均具有确切的效果,不良反应患者均可耐受,但观察组患者的不良反应发生率更低。

Objective To observe the clinical efficacy of XELOX and FOLFOX6 for colorectal cancer. Methods 57 colorectal cancer patients were randomly divided into the observation group （27 cases） and the control group （30 cases）. Patients in the control group were given oxaliplatin ＋ fluorouraeil ＋ calcium folinate, patients in the observation group were given oxaliplatin ＋ eapecitabine,patients in both groups were given 2 or more cycles of chemotherapy, and intensity-modulated radiotherapy, the radiation dose was 60 Gy-70 Gy/33 f-39 f. The objective curative effect of the 2 groups were evaluated according to the standard of WHO ,the acute adverse reactions caused by ehemoradiotherapy were evaluated according to the RTOG and WHO standards. Re- sults The effective rates of the observation group and the control group were 81.5% and 73.3%, the progression-free survival time of patients were 16 months and 18 months ,the 1 year survival rates were 87.6% and 83.4% ,respectively, there was no sta- tistical significance （ P 〉 0.05 ） between the 2 groups. In terms of adverse reactions, hand-foot syndrome was more significant in the observed group （P 〈 O. 05 ） , the incidence of other adverse reactions in the control group was higher, but the difference had no statistical significance （P 〉 0.05 ）. Conclusion XELOX and FOLFOX6 are effective treatment for colorectal cancer with tolera- ble adverse reactions, and the incidence of adverse reactions of patients in the observation group is lower.